ORTHOVISC je viskosuplement velike molekularne mase koji se uspešno koristi preko 20 godina za lečenje bola izazvanog osteoartritisom.

ORTHOVISC PREDNOSTI

• u upotrebi preko 20 godina
• HA nije životinjskog porekla
• snažno i dugotrajno ublažavanje bola tokom 6 meseci^[12]
• može odložiti potrebu za postupkom zamene kolena do 3,6 godina^[13]
• nema potvrđenih pseudoseptičnih reakcija^[14]
• odobren od strane FDA
• koncentracija HA 2ml/30mg

MOLEKULARNA TEŽINA SUPSTANCI
Zbog optimalne molekularne težine snažno se vezuje za površinske receptore ćelija^[5,15,16]

Link: https://www.anikatherapeutics.com/products/pain_management/orthovisc/

[5] Smith MM, Ghosh P. The synthesis of hyaluronic acid by human synovial fibroblasts is influenced by the nature of the hyaluronate in the extracellular environment. Rheumatol Int. 1987; 7(3):113-22.

[12] Brandt KD, Block JA, Michalski JP, Moreland LW, Caldwell JR, Lavin PT. Ecacy and safety of intra-articular sodium hyaluronate in knee osteoarthritis. ORTHOVISC Study Group. Clin Orthop Relat Res 2001;(385):130 – 43.

[13] Altman, R., et. al. Hyaluronic Acid Injections Are Associated with Delay of Total Knee Replacement Surgery in Patients with Knee Osteoarthritis: Evidence from a Large U.S. Health Claims Database. 2015 Dec; doi 10.1371/journal.pone.0145776.

[14] Information from package inserts.

[15] Tobetto K, Yasui T, Ando T, et al. Inhibitory eects of hyaluronan on [14C]arachidonic acid release from labeled human synovial fibroblasts. Jpn J Pharmacol. 1992 Oct;60(2):79-84.

[16] S Gotoh, J Onaya, et al. Eects of the molecular weight of hyaluronic acid and its action mechanisms on experimental joint pain in rats, Ann Rheum Dis 1993;52;817-822.